Percutaneous Inferior Vena Cava—to—Portal Vein Shunt (PIPS) Using a Stent-Graft: Preliminary Results
Purpose: To present preliminary results of an inferior vena cava (IVC)–to—portal vein shunt (PIPS) that is created through the caudate lobe of the liver. Methods: Sixteen patients (13 men; mean age 50 years, range 32–63) were referred for PIPS procedures because of bleeding varices (n = 11), intract...
Gespeichert in:
Veröffentlicht in: | Journal of endovascular therapy 2002-08, Vol.9 (4), p.503-510 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose:
To present preliminary results of an inferior vena cava (IVC)–to—portal vein shunt (PIPS) that is created through the caudate lobe of the liver.
Methods:
Sixteen patients (13 men; mean age 50 years, range 32–63) were referred for PIPS procedures because of bleeding varices (n = 11), intractable ascites (n = 4), and hepatorenal syndrome (n = 1). The severity of liver disease was Child's B in 2 and Child's C in 14. The PIPS was created by a transhepatic puncture through the IVC and the portal vein; an endograft made of polytetrafluoroethylene sutured to a Palmaz stent was placed through a jugular approach.
Results:
In 13 (81%) patients, the portal vein—to—IVC tracts were successfully created. The postprocedural portal vein—IVC gradients varied from 1 to 9 mm Hg (mean 5). There were 2 deaths in the 30-day periprocedural period from adult respiratory distress syndrome and hepatorenal syndrome. A third patient died at 31 days from liver failure owing to continuing alcohol abuse. In addition, there was 1 case of peritoneal bleeding treated with blood product replacement. The follow-up period ranged from 14 to 671 days (mean 343). None of the patients treated for variceal bleeding had another bleeding episode, but 2 patients who had a PIPS procedure for refractory ascites did not benefit from the procedure. Postprocedure, 46% (6/13) of the patients had hepatic encephalopathy, which was unchanged from baseline. The primary and secondary patency rates at 365 days were 60% and 65%, respectively.
Conclusions:
The preliminary results using a stent-graft to create an IVC-portal vein shunt are encouraging and support further work to better determine the role of this procedure. |
---|---|
ISSN: | 1526-6028 1545-1550 |
DOI: | 10.1177/152660280200900420 |